Amgen (AMGN) Tops Q1 EPS by 61c; offers guidance

Amgen (NASDAQ: AMGN) reported Q1 EPS of $4.90, $0.61 better than the analyst estimate of $4.29. Revenue for the quarter came in at $8.15 billion versus the consensus estimate of $8.09 billion.

GUIDANCE:

Amgen sees FY2025 EPS of $20.00-$21.20, versus the consensus of $20.63. Amgen sees FY2025 revenue of $34.3-35.7 billion, versus the consensus of $35.102 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Fluent (FLNT) Tops Q2 EPS by 4c
• The Metals Royalty Company Inc. (TMCR) Reports Q2 Loss of $0.12
• DiaMedica Therapeutics Inc. (DMAC) Reports In-Line Q2 EPS